Physician profile
Thomas Sirrine
NPI 1689900276
$36,839.41
in general payments reported to CMS, 2019-2025
41 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,778 · 2022: $3,544 · 2023: $2,477 · 2024: $5,256 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $11K · Travel and Lodging: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,922.50 |
| Food and Beverage | $11,076.65 |
| Travel and Lodging | $2,518.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $16,267.21 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $14,485.16 | 2021-2025 | Descovy, Yeztugo, Biktarvy |
| Merck Sharp & Dohme LLC | $1,044.78 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $919.40 | 2021 | |
| Janssen Products, LP | $689.26 | 2021-2023 | Symtuza |
| Janssen Biotech, INC. | $588.87 | 2021-2023 | Symtuza |
| Napo Pharmaceuticals INC | $442.28 | 2021-2025 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $378.25 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $339.87 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $282.16 | 2021-2025 | |
| Indivior INC. | $204.92 | 2024-2025 | Sublocade |
| Abbvie INC. | $166.80 | 2021-2022 | |
| Braeburn INC. | $163.76 | 2024-2025 | Brixadi |
| Abbott Laboratories | $76.52 | 2021 | |
| Pfizer INC. | $74.83 | 2021-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sirrine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.